1、Q2 2022www.deep-pharma.techinfodeep-pharma.techEpigenetic Drugs:From Cancer to AgingApproach of the Report3Executive Summary4Mindmap5Introduction to Epigenetics5Targets for EpiDrugs9Rise of EpiDrugs Development13Growth of Scientific Interest in EpiDrugs15Key Market Players17Selected Collaborations18

2、EpiDrugs Repurposing19Epigenetics and Cancer21Table of ContentsBiological Basis of Cancer22Epigenetics of Cancer24DNA Methylation in Cancer25Chromatin in Cancer28Combination Therapy in Cancer33Epigenetics and Aging40Aging Epigenome42Market Overview49Key Takeaways56Appendix:List of Entities57Disclaim

3、er70Deep Pharma Intelligence2Relying on various research methods and analytics techniques,the analysis provides a comprehensive overview of the Preclinical and Clinical Trials Industry.This approach has certain limitations,especially when using publicly available data sources and conducting secondar

4、y research.Deep Pis not responsible for the quality of the secondary data presented herein;however,we do our best to eliminate the said risks using different analytics techniques and cross-checking data.Please note that we did not deliberately exclude certain companies from our analysis.Nor was it d

5、ue to the data-filtering method used or difficulties encountered.The main reason for their non-inclusion was incomplete or missing information in the available sources.Approach of the ReportIndustry-Specialised Databases Data SourcesMedia Overview(Articles and Press Releases)Industry Reports and Rev

6、iewsPublicly Available Sources(Websites)DescriptiveAnalysisComparative AnalysisQualitative Data CollectionMixed Data ResearchData TriangulationData FilteringApplied Research and Analytics MethodsDatabase75Drugs80Companies85R&D CentresThe database was formed based on:the identification of companies t